Bruce Haffty, MD, and Mutlay Sayan, MD, on building radiation oncology at Rutgers, the future of the field, and a remarkable journey from eastern Turkey to Harvard faculty.
|Articles|April 1, 2007
Oncology NEWS International
- Oncology NEWS International Vol 16 No 4
- Volume 16
- Issue 4
GlaxoSmithKline Submits BLA for Cervarix HPV Vaccine
GlaxoSmithKline Submits BLA for Cervarix HPV Vaccine
Advertisement
PHILADELPHIA, Pennsylvania—GlaxoSmithKline has submitted to the FDA a Biologics License Application (BLA) for Cervarix (human papillomavirus vaccine, AS04 adjuvant-adsorbed), its cervical cancer candidate vaccine. The vaccine is formulated with a proprietary adjuvant system called AS04 containing aluminum hydroxide and monophosphoryl lipid A. The submission includes data from clinical trials in almost 30,000 females age 10 to 55 reflecting an ethnically diverse population, the company said.
Articles in this issue
over 19 years ago
Curcumin Evaluated for the Treatment of Pancreatic Cancerover 19 years ago
Tykerb Approved for Metastatic HER2+ Breast Cancerover 19 years ago
Drug for BPH May Also Reduce the Risk of Prostate Cancerover 19 years ago
Phase III Trial of Prostvac-VF Is Launchedover 19 years ago
Electronic System Reminds Patients to Schedule Examsover 19 years ago
Phase II Trial of Panzem for Renal Cell Carcinoma Initiatedover 19 years ago
Chemotherapy May Enrich Tumorigenic Cells in Breast Caover 19 years ago
Watchful Waiting Management for Prostate Ca a Hard SellAdvertisement
Related to this article
Marcio A. Fagundes, MD, discussed disease control by risk group among 404 patients with prostate cancer treated with intensity-modulated proton therapy.
The approval expands the indication of pirtobrutinib to patients with previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma with no known 17p deletion.
Community physicians must be “smart” when it comes to initiating outpatient care with agents like ramantamig for multiple myeloma, according to Jeffrey V. Matous, MD.
In the phase 3 Alliance A071801 trial, postoperative fractionated SRS improved surgical bed control vs single-fraction SRS without added toxicity.
In the phase 3 evERA trial, interim overall survival data showed a positive trend in favor of giredestrant/everolimus vs endocrine therapy plus everolimus.
William A. Hall, MD, reviews resection rates, surgical complications, and SBRT target volumes from the SOFT Preop study in pancreatic cancer.
Andy Liao, MD, discusses the distribution of KRAS mutations in biliary tract cancer and the different classes of KRAS inhibitors in development.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA OKs Pirtobrutinib in Frontline CLL/SLL
2
Multimodal Biopsy Combo Shows Low Morbidity in Suspected Prostate Cancer
3
Assessing IMPT Outcomes Across Localized Prostate Cancer Risk Groups
4
SBRT Matches Disease Control of Prostatectomy in Localized Prostate Cancer
5